New-generation polymyxins that target multidrug-resistant Gram-negative bacteria. The lead candidate novel lipopeptide antibiotic is in advanced preclinical development and has demonstrated superior in vivo efficacy and safety over currently used polymyxin antibiotics.
[更多]
New-generation polymyxins that target multidrug-resistant Gram-negative bacteria. These novel lipopeptide antibiotics have demonstrated superior in vivo efficacy and toxicity overcurrent polymyxin antibiotics.
[更多]
Vaccine comprising live attenuated recombinant alphavirus vaccine comprising mutated capsid protein
[更多]